Onco-Innovations Advances Progress Towards First-in-Human Trial with Avance Clinical Start-Up Agreement

Executive Summary

• Onco-Innovations Limited has entered into a Start-Up Agreement with Avance Clinical Pty Ltd, a leading contract research organization (CRO), to initiate key regulatory and clinical documentation for its lead candidate, a first-in-class, polymer-encapsulated Polynucleotide Kinase Phosphatase (PNKP) inhibitor.
• The collaboration aims to lay the groundwork for regulatory clearance and clinical trial readiness, specifically targeting advanced-stage cancers with PTEN1 or SHP-12 deficiency.
• Avance Clinical will provide expert clinical and regulatory support, including the development of an Investigator’s Brochure, a detailed clinical trial protocol, and preparation for a pre-IND meeting with the U.S. FDA.

Key Details

• Agreement Type: Start-Up Agreement with Avance Clinical Pty Ltd.
• Target Therapy: Exclusively licensed Polynucleotide Kinase Phosphatase (PNKP) inhibitor, described as a first-in-class, polymer-encapsulated therapy.
• Target Indication: Advanced-stage cancers with PTEN1 or SHP-12 deficiency.
• Key Deliverables from Avance Clinical:
  • Development of an Investigator’s Brochure summarizing the drug's preclinical performance.
  • Authorship of a detailed clinical trial protocol.
  • Independent medical and statistical review related to a Phase I clinical study.
  • Nonclinical gap analysis to identify remaining preclinical work required for a future Investigational New Drug (IND) application.
  • Planning and preparation of a pre-IND meeting with the U.S. Food and Drug Administration (FDA).
• Strategic Goal: To align trial design with FDA expectations, reduce development risk, and secure regulatory approval for human testing.

Notable Quotes

• "This collaboration with Avance is another example of our progress as we continue to move towards discovery to clinical development. It's about turning promising science into a real clinical opportunity for patients. Their regulatory and operational expertise will be essential in shaping a trial that is not only scientifically sound but also built for execution. We're excited to enter this collaboration with Avance," stated Thomas O'Shaughnessy, CEO of Onco-Innovations.